ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

FDBK Feedback Plc

60.50
0.00 (0.00%)
19 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB00BJN59X09 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 60.50 60.00 61.00 60.50 60.50 60.50 14,770 07:44:37
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electronic Computers 1.03M -2.92M -0.2188 -2.77 8.07M
Feedback Plc is listed in the Electronic Computers sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 60.50p. Over the last year, Feedback shares have traded in a share price range of 58.00p to 150.00p.

Feedback currently has 13,334,659 shares in issue. The market capitalisation of Feedback is £8.07 million. Feedback has a price to earnings ratio (PE ratio) of -2.77.

Feedback Share Discussion Threads

Showing 7776 to 7798 of 14875 messages
Chat Pages: Latest  319  318  317  316  315  314  313  312  311  310  309  308  Older
DateSubjectAuthorDiscuss
14/1/2020
08:56
What do you make of this tweet especially the highlighted part?

Crucially, within this partnership, CADRAN is provided under licence (with Feedback PLC retaining all associated IP) so represents a low cost revenue stream which can parallel the roll out and success of #Bleepa without directing resource away from it

Is it going to be another SAAS model?
Is Bleepa a success yet?

ged5
14/1/2020
06:57
I'm not getting some posts that's why I've found and posted sorry. But I cant see that.
demonboy
14/1/2020
00:57
Demonboy - See post #4279.

Specifically -

lr2
14/1/2020
00:41
https://www.google.com/url?sa=t&source=web&rct=j&url=The Insight Essentials™ DRF Digital Imaging System is designed to replace the video camera and user interface on the following FDA cleared R&F fluoroscopic imaging systems employing an image intensifier: GE Advantx, GE Legacy, GE P500 and Shimadzu YSF300. The x-ray generator, beam-limiting device and patient positioner, necessary for a full fluoroscopy system are not part of the subject device. The Insight Essentials™ DRF Digital Imaging System allows the operator to view and enhance high-definition fluoroscopy images. High resolution digital spot images may also be acquired at single or rapid acquisition rates, up to 30 fps. Images may be viewed and enhanced enabling the operator to bring out diagnostic details difficult or impossible to see using conventional imaging techniques. Images can be stored locally for short term storage. The Insight Essentials™ DRF Digital Imaging System enables the operator to produce hardcopy images with a laser printer or send images over a network for longer-term storage. The major system components include: a fluoroscopic video camera, monitors, and an image processor PC. 3. Indications for Use Intended for use by a qualified/trained doctor or technician on both adult and pediatric subjects for obtaining fluoroscopic radiographic images of the skull, spinal column, chest, abdomen, extremities, and other body parts. 4. Summary of Design Control Risk Management The Insight Essentials™ DRF Digital Imaging System has been developed to provide medical professionals optimized workflow when imaging patients while meeting critical functional requirements and international safety standards. The risks and thehazardous impact of the device design were analyzed with FMEA method. The uspecific risk control and protectiv8e measures to mitigate the risks from the device design and production phase were reviewed and implemented in the new product design phase. The overall assessment concluded that all risks and hazardous conditions identified arising from the design and production were successfullymitigated and accepted.
demonboy
13/1/2020
22:47
Nice work LR2. Texrad is alive and well after all.
Also, not a bad announcement this morning from the company, certainly warranted a few percentage rise but hey ho this is Aim!

petekand
13/1/2020
16:54
You're welcome Davy. Hope all is well with you.

Ged, your guess is as good as mine about an announcement. Would be nice if they did. Would have to assume the Imaging Engineering RNS has more importance than we originally thought if they do not. Surely must be financially beneficial to the company in some way. Another income stream I guess.

lr2
13/1/2020
16:48
Ged, they aren’t getting it free!
ducatiman
13/1/2020
16:46
Good question Duc - not sure of answer.

Posed the same to StoneChecker personnel in the past and they said "It don't matter" or words to that effect. Then, again, they'd say anything for a quiet life.

lr2
13/1/2020
16:45
Thanks LR2. Do you think the company will make an announcement about this use of TexRAD? Will FDBK receive any licencing fee?
ged5
13/1/2020
16:42
Now that's what I'm talking about!

Thanks LR2

davydoo
13/1/2020
16:40
I did not LR2 but this is why we invested here in the first place! Question:- where do they stand when Texrad does not have FDA approval? Edit, or like stone checker, it is not needed?
ducatiman
13/1/2020
16:28
Did you notice it was a Berkshire Hathaway company that posted it? That bloke Warren's a clever old so-and-so.
lr2
13/1/2020
16:23
Indeed not LR2.
ducatiman
13/1/2020
16:22
Not just a pretty face, Duc.
lr2
13/1/2020
16:19
Great find LR2!!!!
ducatiman
13/1/2020
16:10
And now we have -

Breakthrough Radiomic Technology Patent Issued to Imaging Endpoints



"The signature is derived from processing mammography data using a Quantitative Textural Analysis™ platform (TexRAD); generating respective histograms and related quantitative metrics, and performing logistical regression to yield a model predictive signature."

lr2
13/1/2020
15:41
https://www.proactiveinvestors.co.uk/companies/news/215150/feedback-starts-discussions-about-bleepa-trials-with-nhs-215150.html
demonboy
13/1/2020
15:38
I thought this was more pertinent to today's announcement:-

Crucially, within this partnership, CADRAN is provided under licence (with Feedback PLC retaining all associated IP) so represents a low cost revenue stream which can parallel the roll out and success of #Bleepa without directing resource away from it

ged5
13/1/2020
15:36
https://www.med-technews.com/news/imaging-company-to-launch-clinical-messaging-app-at-nhs-expo/
demonboy
13/1/2020
15:24
https://www.homecareinsight.co.uk/4-5m-investment-to-bridge-technology-gap-between-the-nhs-and-social-care/
demonboy
13/1/2020
15:19
https://twitter.com/BleepaMe/status/1166697001980964865?s=20
demonboy
13/1/2020
14:04
The major factors for the growth of the fluoroscopy devices market include the rising demand for minimally-invasive surgeries, growing geriatric population, prevalence of chronic diseases, and increasing use of fluoroscopy in pain management.

North America is holds a major share for the fluoroscopy devices market, and is expected to show a similar trend over the forecast period, without significant fluctuations. The United States has the largest installed base of fluoroscopes in the world. An estimated 4-10 million interventional pain procedures are performed annually in the country, with at least 50% of those performed under fluoroscopy.

ged5
13/1/2020
12:44
A small number of initial installations have already been performed by Imaging Engineering and the first license fees have now been received by Feedback Medical, the company said.
demonboy
Chat Pages: Latest  319  318  317  316  315  314  313  312  311  310  309  308  Older